Refine your search
Content Type
Author
- Mark Troutman (7)
- Michael Frank (2)
- Jeffrey Miller (2)
- Brian Dale Shively (2)
- Ankit Nanda (2)
- William K Tyler (1)
- William A Halvorson (1)
- Tasha Barbour (1)
- Steven J Gaspar (1)
- Ronald Poon-Affat (1)
- Robert Kreager (1)
- Robert Beal (1)
- Raymond F McCaskey (1)
- Miriam E Kaufman (1)
- Michael McLean (1)
- Michael Lachance (1)
- Michael Johnson (1)
- Michael A Kemp (1)
- Mehboob Khoja (1)
- Mark Richard Troutman (1)
- Lindsay Meisinger (1)
- Larry Stern (1)
- Kyle Proebsting (1)
- Kristi Bohn (1)
- Kevin Gabriel (1)
- Karl Ideman (1)
- John W Coons (1)
- John Dante (1)
- Jerome Winkelstein (1)
- Jeffrey E Babino (1)
- Jason Alvarez (1)
- James O'Connor (1)
- Jack Reid (1)
- Harry L Sutton (1)
- Edmund Santiago (1)
- EVELYN S STRAVOLEMOS (1)
- Donald Solow (1)
- Donald Behan (1)
- David Nussbaum (1)
- Daniel Wolak (1)
- Carol B Adams (1)
- Calvert A Jared (1)
- Arthur Garrison (1)
- Albert J Reznicek (1)
- Show More Show Less
Site
Topic
- Health reinsurance (31)
- Health insurance (6)
- Life reinsurance (5)
- Stop-loss insurance (4)
- Reinsurance (3)
- Health & Disability (3)
- Reserving - Reinsurance (2)
- Product development - Reinsurance (2)
- Pricing - Reinsurance (2)
- Health care reform (2)
- Disability insurance (2)
- General reinsurance (1)
- Marketing and distribution - Reinsurance (1)
- Long-term care reinsurance (1)
- Financial reporting for reinsurance (1)
- Health policy (1)
- Public Policy, Law & Regulation (1)
- Statutory accounting (1)
- Generally Accepted Accounting Principles [GAAP] (1)
- Health economics (1)
- Financial markets (1)
- Show More Show Less
31
-
31
of
31
results (0.17 seconds)
Sort By:
-
A Survey of the Fast-Evolving Landscape for Cell and Gene Therapy Coverage in the United States
A Survey of the Fast-Evolving Landscape for Cell and Gene Therapy Coverage in the United States This article attempts to make a modest contribution to the dialogue on the potential and risks ...Description: This article attempts to make a modest contribution to the dialogue on the potential and risks associated with novel treatments such as cell & gene therapies. With a fast-expanding roster of what are believed to be one-time treatments at ever increasing price points aimed at curing a wider swatch of the population, they are as much a source of relief for patients stuck in medical limbo, as they are a source of anxiety for payers.
Hide- Authors: Ankit Nanda
- Date: May 2024
- Competency: External Forces & Industry Knowledge; Results-Oriented Solutions
- Publication Name: Health Watch
- Topics: Health & Disability; Health & Disability>Health insurance; Reinsurance>Health reinsurance